This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoGenomics Appoints Dr. Maher Albitar As Chief Medical Officer

FT. MYERS, Fla., Jan. 9, 2012 /PRNewswire/ --  NeoGenomics, Inc. (NASD OTC BB: NGNM), a leading provider of cancer-focused genetic testing services, announced today the appointment of Dr. Maher Albitar as Chief Medical Officer and Director of Research and Development. 

From 2003 to 2010, Dr. Albitar served as the Medical Director for Hematopathology and Oncology, and Chief of Research and Development, for Quest Diagnostics Nichols Institute.  He was responsible for the development of numerous tests and inventions in molecular testing and plasma-based testing.  From 1991 through 2003, Dr. Albitar held various faculty positions at The University of Texas MD Anderson Cancer Center where he also served as Director of the Leukemia and Molecular Laboratory in the Division of Laboratory Medicine and Pathology Medicine.  He was also a tenured full professor in the Departments of Leukemia and Pathology.  Most recently, Dr. Albitar served as the Chief Medical Officer of Health Discovery Corporation ("HDC"), and he will remain as a member of the Board of Directors of HDC. 

Dr. Albitar attended medical school at Damascus Medical School, completed his Anatomic Pathology and Clinical Pathology Residency at Brown University, and completed a Hematopathology Fellowship as well as a post-doctoral training in Genetics at the Howard Hughes Medical Institute at the University of Pennsylvania.  He holds numerous patents and has authored more than 300 peer-reviewed papers, book chapters, and review articles.  Dr. Albitar has served on a variety of medical editorial review boards and is a frequent guest speaker at national and international conferences. 

Doug VanOort, Chairman and CEO, commented, "We are delighted to welcome Dr. Maher Albitar to our company.  Our company's roots are in the diagnosis of hematologic cancers, and Dr. Albitar is world renowned for his expertise in Hematopathology and Molecular Oncology.  Additionally, Dr. Albitar's passion for innovation and development of new molecular genetic tests will enhance our ability to develop and launch novel new tests targeting a variety of cancers.  We expect innovation and the launch of proprietary products to be an ever more important driver of future growth for our company."

Dr. Albitar commented, "NeoGenomics has established an excellent reputation as one of the premier cancer testing laboratories in America and I am honored to join the executive team.  The recent agreement between NeoGenomics and Health Discovery Corporation provides the perfect environment for innovation and the development of clinical models based on pattern recognition and multi-analyte analysis.  I look forward to helping NeoGenomics commercialize a number of new proprietary laboratory developed tests and other products based on combining recent developments in molecular techniques with HDC's pattern recognition technology." 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs